摘要:
[Problem to be Solved]The present invention provides a compound promoting osteogenesis. [Solution] The present invention provides a compound having the following general formula (I) wherein R1 is H or alkyl, R2 is RaS—, RaO—, RaNH—, Ra(Rb)N— or cyclic amino, and Ra and Rb are alkyl which may be substituted, cycloalkyl which may be substituted, or the like, or a pharmacologically acceptable salt thereof.
摘要:
The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.
摘要:
An optical disc drive device has an FE signal generator which generates a focus error signal, a TE signal generator which generates a tracking error signal, a return beam detector which detects a return beam reflected by an optical disc after irradiated by an optical pickup to generate a return beam level signal, a return beam gain setting part which sets amplitude adjustment amount of the return beam level signal so that a signal level of the return beam level signal generated by the return beam detector coincides with a predetermined reference level, an FE gain setting part which sets amplitude adjustment amount of the focus error signal in accordance with the signal level of the return beam level signal adjusted by the return beam gain setting part so that a signal amplitude of the focus error signal is constant, and a TE gain setting part which sets amplitude adjustment amount of the tracking error signal in accordance with the signal level of the return beam level signal adjusted by the return beam gain adjustment part so that a signal amplitude of the tracking error signal is constant.
摘要:
Grid array electronic component, wiring-strengthening method and producing method wherein a grid array electronic component in which a grid array LSI chip 2 having a large number of lands 3 connected to a large number of lands 13 through connecting means 30, the lands 13 are connected to a wire 4 of a printed wiring board 1, an auxiliary land 5 is formed at a connection portion 31 of the lands 13 on the printed wiring board 1 corresponding to the lands 3 of a corner portion of the grid array LSI chip 2 connecting the wire 4 and the concentration of stress of the connection portion 31 is moderated, thereby providing the effect that the brake of the wire in the connection portion 31 is prevented.
摘要:
Compounds having activity against production of inflammatory cytokines of formula (I)′: A′ is pyrrole; R1′ is aryl or heteroaryl; R2′ is heteroaryl having at least one nitrogen atom; R3′ is (IIa)′, (IIb)′ or (IIc)′: m′ is 1 or 2; one of D′ and E′ is nitrogen and the other is >C(R5′)—, R5′ is hydrogen, Substituent α′ or Substituent β′; B′ is nitrogen-containing 4- to 7-membered heterocyclic; R4′ is 1 to 3 substituents from Substituent α′, Substituent β′ and Substituent γ′; R1′ and R3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2′; Substituent α′: hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa′Rb′; Ra′ and Rb′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra′ and Rb′ with the nitrogen atom form a heterocyclyl; Substituent β′: alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent γ′: oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
摘要翻译:具有抗式产生式(I)的炎性细胞因子的化合物的化合物:A'是吡咯; R 1是芳基或杂芳基; R 2是具有至少一个氮原子的杂芳基; (IIa)',(IIb)'或(IIc)':m'为1或2; D'和E'之一是氮,另一个是> C(R 5') - ,R 5'是氢,取代基α'或取代基β'; B'是含氮的4-至7-元杂环; R 4'是1至3个取代基α',取代基β'和取代基γ'的取代基; R 1'和R 3'连接到与R 2'连接的吡咯原子相邻的吡咯的两个原子上; 取代基α':羟基,硝基,氰基,卤素,烷氧基,卤代烷氧基,烷硫基,卤代烷硫基或-NR a R b b。 R a,O和R b'是氢,烷基,烯基,炔基,芳烷基或烷基磺酰基,或者R a'和R“ b'与氮原子形成杂环基; 取代基β':烷基,烯基,炔基,芳烷基或环烷基; 取代基γ':氧代,羟基亚氨基,烷氧基亚氨基,亚烷基,亚烷基二氧基,烷基亚磺酰基,烷基磺酰基,芳基,芳氧基,亚烷基或芳烷基。
摘要:
A bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. The compound has the following formula (I): wherein A represents pyrrole or pyrazole, R1 represents an aryl group or a heteroaryl group which may be substituted, R2 represents a heteroaryl group which may be substituted, and R3 represents an indolizine group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
摘要:
Compounds of formula (I) and (II): ##STR1## �wherein R is hydrogen, halogen or alkyl; R.sup.1 is alkyl, amino or substituted amino; R.sup.2 is optionally substituted phenyl; R.sup.3 is hydrogen, halogen or optionally substituted alkyl; R.sup.4 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl! have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.
摘要:
Apparatus for folding a sheet-form material in a zigzag fashion. Lower and upper guide members are provided in opposed relation in a frame. Sheet-form material is placed under tension between the upper and lower guide members. Plural lower up-and-down movable members are arranged at regular intervals on the lower guide member. Plural upper up-and-down movable members are arranged on the upper guide member at regular intervals and at positions alternate with the lower up-and-down movable members. Fold imparting members are arranged respectively at upper ends of lower up-and-down movable members and at lower ends of upper up-and-down movable members. Upper and lower up-and-down movable members are driven to move toward each other, sequentially from one end side of the upper and lower guide members and toward the other end side, to give folds to the sheet-form material.
摘要:
Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof:
摘要:
Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof